Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lagevrio Japan’s Top-Seller Drug in July-September, 2 Other COVID Meds Make Top 10: IQVIA
November 20, 2023
- Santen Snags European OK for Glaucoma/Ocular Hypertension Drug
November 20, 2023
- Xtandi Approved in US for Prostate Cancer in Earlier Setting
November 20, 2023
- Janssen Files Bispecific Antibody Amivantamab for NSCLC in Japan
November 20, 2023
- Takeda Files CMV Drug Maribavir in Japan
November 20, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- Astellas to Acquire US Upstart Propella for Prostate Cancer Drug
November 17, 2023
- Japanese Pricing Rules Don’t Fully Capture Value of New Modalities, “No” to CEA Expansion: Janssen Exec
November 17, 2023
- Novo Nordisk Curbs Insulin Shipments Due to Surge in Demand for Diabetes Meds
November 17, 2023
- Astellas, University of Tsukuba Tie Up in Drug Discovery and Startup Incubation
November 17, 2023
- Xocova, Dayvigo Again Winner in Sept Rep Promotion Rankings for GPs, HPs: Intage
November 17, 2023
- AbbVie Japan Files Rinvoq 30 mg Regimen for Age 12-Plus Atopic Dermatitis Patients
November 16, 2023
- Change in Dynamics? Suzuken Emerges as No. 2 among Big 4 Japan Wholesalers
November 15, 2023
- Kao, NANO MRNA to Initiate Joint Research for mRNA Drug Discovery
November 15, 2023
- iPark Institute Inks Collaboration Pact with South Korean Government
November 14, 2023
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
- Taisho Hits “Reset” Button for Pharma Biz with 600-Plus Job Cuts
November 14, 2023
- Ajinomoto to Acquire US Gene Therapy CDMO for US$554 Million
November 14, 2023
- UCB Seeks Hidradenitis Suppurativa Nod for Bimzelx in Japan
November 13, 2023
- Otsuka Files NDA for Lupus Nephritis Drug in Japan
November 13, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…